Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

about

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

Item

http://www.wikidata.org/entity/Q44062774

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

@en

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

@nl

type

Item

label

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

@en

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

@nl

prefLabel

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

@en

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

@nl

P1476

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

@en

P2093

Antonia Ridolfi

http://www.w3.org/2001/XMLSchema#string

Carlo Carnaghi

http://www.w3.org/2001/XMLSchema#string

Do-Youn Oh

http://www.w3.org/2001/XMLSchema#string

Edward M Wolin

http://www.w3.org/2001/XMLSchema#string

Fabian Herbst

http://www.w3.org/2001/XMLSchema#string

James C Yao

http://www.w3.org/2001/XMLSchema#string

Jonathan Strosberg

http://www.w3.org/2001/XMLSchema#string

Marianne E Pavel

http://www.w3.org/2001/XMLSchema#string

Roberto Buzzoni

http://www.w3.org/2001/XMLSchema#string

Rodney Pommier

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

P304

5013-5030

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S142087

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Juan Valle

Nicola Fazio

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29081664

http://www.w3.org/2001/XMLSchema#string

P932

5652899

http://www.w3.org/2001/XMLSchema#string